Fig. 3 | Leukemia

Fig. 3

From: Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Fig. 3

a Progression-free survival by the Independent Review Committee (IRC) per the Lugano classification. Kaplan–Meier plot for progression-free survival (PFS; shown as the percentage of patients alive without disease progression) for the 70 efficacy-evaluable patients. The median PFS was not reached after a median follow-up of 9.6 months. b Duration of response by IRC per the Lugano classification with objective response. Kaplan–Meier plot for DOR for all 61 patients who had a response. The median DOR was not reached after a median follow-up of 6.7 months after the initial response. c Progression-free survival by IRC per response category (complete response or partial response)

Back to article page